secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001628280-22-012652
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M
--------------------------------------------------------------------------

- Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).
- Phase 3 trial of relacorilant in platinum-resistant ovarian cancer to start this quarter.
- GRATITUDE I/II data for miricorilant in antipsychotic weight gain expected Q4 2022.
- Relacorilant NDA for Cushing's syndrome now expected H2 2023 (pandemic delays).
- Operating expenses $66.9M (+12% YoY) on expanded R&D and legal costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022012652/0001628280-22-012652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022012652/cort-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-012652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer